Saba Pharmaceuticals was established by eight shareholders, majority of which were pharmacists in 1967. The production started with several pharmaceuticals in a small laboratory in Eminonu. Increased product portfolio created the demand of moving to a new site in Aksaray in 1978 and the production facility stayed there 22 years.

Saba Pharmaceuticals, based on the philosophy of “health and happiness” has invested heavily to the continuous development to provide better standards to both its employees and Turkish population for forty years. 


Our Mission;

To serve Turkish people with cost effective pharmaceutical products against diseases and to help them live happier.and healthier enhance value of human life, protect and improve healthcare. 

Our Vision;

We will present high quality and cost-effective treatment alternatives with our existing product portfolio and new products that we will add to the product line of our company as one of the rising stars of the Turkish Pharmaceutical Market.       


• Resilience

• Ownership 

• Innovation and development

• Trustworthiness

• Human focus

• Teamwork



Philipp Haas

Chairman of the Board of Directors and CEO

Philipp Haas, Chairman of the Board of Directors and CEO, Saba İlaç Sanayii ve Ticaret A.Ş., received his MBA in banking from the University of St. Gallen. He speaks German, English, French, Spanish, Portuguese, Italian and Turkish fluently. Philipp Haas held investment consultant and executive posts since 1992, and has vast experience in East European markets, in particular Turkey. He was involved in several reorganization projects in Ukraine and Turkey, and sat on several executive boards, representing the interests of foreign corporate investors in the 90s, including Rogan Brewery of Ukraine, and Net Holding of Turkey.

Philipp Haas has broad experience in the pharmaceutical industry, and had focused investments at East Europe when working as an advisor to investment trusts for the pharmaceutical sector in the developing world. These include Slovakpharma, which was later renamed to Zentiva.

Haas held senior posts in other companies within the group, and the post of chairman of the board of directors at EastPharma Ltd. DEVA Holding A.Ş. New Life Yaşam Sigorta A.Ş. ile Eastpharma İlaç Üretim Pazarlama San. ve Tic. A.Ş., and member of the board of directors at EastpharmaSarl, Lypanosys Pte Limited and EastPharma Canada Ltd.


Mesut Çetin

Vice-Chairman of the Board of Directors & CFO

Mesut Çetin, Vice-Chairman of the Board of Directors and CFO, Saba İlaç Sanayii ve Ticaret A.Ş., received his Bachelor’s Degree in Teaching Mathematics from Boğaziçi University, and his EMBA from Koç University.

From 1999, he worked in various roles, including analyst, trader and project manager, at GEM Global Equities Management S.A, and between years 2005 and 2007 assumed the role of executive responsible for operations within the same group.

Mesut Çetin sits on the board of directors of Turkish Association of Pharmaceutical Manufacturers (TİSD), representing  Saba İlaç Sanayii ve Ticaret A.Ş, and holds the position of , Member of the Board of Directors at EastPharma Ltd and EastPharma Canada Ltd. and Vice-Chairman of the Board of Directors and CFO at DEVA Holding A.Ş.

Ayşecik Haas

Member of the Board of Directors

Ayşecik Haas, Member of the Board of Directors, Saba İlaç Sanayii ve Ticaret A.Ş., graduated from Ankara Özel Yükseliş Koleji in 1991, and afterward received her Bachelor’s Degree in Electric and Electronic Engineering from Eastern Mediterranean University, and her Master’s Degree in Economics from Texas Tech University.

She embarked on her professional career in Turkey working in various engineering roles at Emek Elektrik ve Beko Elektronik, and after receiving her master’s degree in economics, worked for some time in finance roles in New York, and as an investment specialist, briefly, at Hattat Holding after repatriating to Turkey. In 2008, Ayşecik Haas held the post of General Manager at NAR Group, a media organization, and currently sits on the board of directors of DEVA Holding A.Ş. and Saba İlaç San. Ve Tic. A.Ş.